261G000317 - VESTRONIDASE ALFA 10 MG / 5 ML INJ

This tender, identified by the reference number 261G000317, concerns the procurement of Vestronidase Alfa, a medication supplied in an injectable form at a concentration of 10 mg per 5 ml. Vestronidase Alfa is a therapeutic enzyme used in the treatment of specific rare genetic disorders, notably Mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux-Lamy syndrome. This condition results from a deficiency in the enzyme N-acetylglucosamine-6-sulfatase, leading to the accumulation of glycosaminoglycans in various tissues and organs, causing severe health problems. The tender likely seeks a supplier for this specialized pharmaceutical product, which is crucial for managing the symptoms and progression of MPS VI. The specified dosage and form (10 mg/5 ml injection) indicate a precise requirement for the medication. This procurement is essential for healthcare providers or national health systems to ensure continuous access to this life-altering treatment for patients diagnosed with MPS VI. The tender reference number suggests it is part of a larger procurement framework or a specific call for tenders within a healthcare institution or government agency responsible for pharmaceutical supplies. Further details regarding quantities, delivery schedules, and specific tender conditions would be found in the full tender documentation.

This is a supplies contract in the health and medical services, information and communication technology and general supplies sectors, with a focus on artificial intelligence. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 465,263.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.